HbA1c levels in individuals heterozygous for hemoglobin variants

RICARDO SILVA TAVARES¹, FÁBIO OLIVEIRA DE SOUZA²*, ISABEL CRISTINA CARVALHO MEDEIROS FRANCESCANTONIO²,

WESLEY CARVALHO SOARES¹, MAURO MEIRA MESQUITA³

¹Undergraduate Degree in Biomedicine from Pontifícia Universidade Católica de Goiás (PUC Goiás), Goiânia, GO, Brazil
²MD and PhD Professor at the School of Medical, Pharmaceutical and Biomedical Sciences, PUC Goiás, Goiânia, GO, Brazil
³MSc Professor at the School of Medical, Pharmaceutical and Biomedical Sciences, PUC Goiás, Goiânia, GO, Brazil

SUMMARY

Objective: To evaluate the levels of glycated hemoglobin (HbA1c) in patients heterozygous for hemoglobin variants and compare the results of this test with those of a control group.

Method: This was an experimental study based on the comparison of HbA1c tests in two different populations, with a test group represented by individuals heterozygous for hemoglobin variants (AS and AC) and a control group consisting of people with electrophoretic profile AA. The two populations were required to meet the following inclusion criteria: Normal levels of fasting glucose, hemoglobin, urea and triglycerides, bilirubin > 20 mg/dL and non-use of acetylsalicylic acid. 50 heterozygous subjects and 50 controls were evaluated between August 2013 and May 2014. The comparison of HbA1c levels between heterozygous individuals and control subjects was performed based on standard deviation, mean and G-Test.

Results: The study assessed a test group and a control group, both with 39 adults and 11 children. The mean among heterozygous adults for HbA1c was 5.0%, while the control group showed a rate of 5.74%. Heterozygous children presented mean HbA1c at 5.11%, while the controls were at 5.78%. G-Test yielded p=0.93 for children and p=0.89 for adults.

Conclusion: Our study evaluated HbA1c using ion exchange chromatography resins, and the patients heterozygous for hemoglobin variants showed no significant difference from the control group.

Keywords: glycated hemoglobin A, ion exchange chromatography, hemoglobins.

INTRODUCTION

Glycated hemoglobin (HbA1c) is used to assess the efficacy of diabetes treatment and is a paramount control for better quality of life among patients. The test reveals the mean blood glucose in the last four months before the test, based on the turnover of hemoglobin, which lasts 120 days.¹ Clinical data show that the mean level of blood glucose in the 20 to 30 days preceding blood sampling contributes around 50% of the end result of HbA1c, while the mean level in the prior 90 to 120 days contributes only 10%. Thus, this method can detect large variations in blood glucose.²,³

HbA1c was defined as a diagnostic method for diabetes mellitus, with a threshold of 6.5% for adults. The test should be performed using a method that is certified by the National Glycohemoglobin Standardization Program (NGSP) and standardized or traceable to the Diabetes Control and Complications Trial (DCCT) reference.⁴ For the measurement of HbA1c, it is desirable that laboratories use NGSP certified methods, and it is important to note that high-performance liquid chromatography (HPLC) is not the only method available for the measurement of HbA1c. Several other diagnostic tests that use non-HPLC methods are also certified. The following methods were also evaluated by the NGSP: turbidimetric immunoassay, electrophoresis, ion exchange chromatography and enzymatic assay.⁵-⁸

HbA1c has several advantages over fasting glycemia, including greater convenience, since fasting is not necessary, evidence suggesting greater pre-analytical stability, and fewer day-to-day disturbances during periods of stress and disease.⁴
For a reliable HbA1c result, some possible interferers must be considered, including the labile fraction and sample preservation. In addition to the variables mentioned above, some factors such as hyperbilirubinemia, hypertriglyceridemia, hyperuremia, chronic alcoholism, chronic ingestion of salicylates and opiate dependence can significantly alter HbA1c results, producing falsely increased results. False-low results are observed in the presence of large amounts of vitamins C and E, which are described as inhibitory factors for hemoglobin glycation.

Hemoglobinopathies and hemoglobin variants are also interfering factors, the latter being characterized by changes in hemoglobin structure caused by differences in the amino acid sequence of globin chains.

Hemoglobin (Hb) is a spheroidal molecule, which is located inside the red blood cells and whose main function is the transport of oxygen to the tissues. Its structure is composed of four subunits formed by two pairs of identical polypeptide chains, called globins, each bound to a heme group. The hemoglobin profile of a normal adult contains about 97% of HbA (two α-globin chains and two β-globin chains, represented as α2β2), 2% of HbA2 (α22) and 1% of fetal Hb (HbF, represented as α2γ2), which is the predominant Hb during intrauterine life.

HbA1c is a subtype derived from the binding of HbA1 by means of an irreversible non-enzymatic reaction between blood glucose and the N-terminal amino acid valine of the beta chain. The change in hemoglobin levels observed in heterozygous individuals may interfere with test results, which is the case of HbA1c. Thus, our objective in the present study was to verify A1c levels in patients heterozygous for hemoglobin variants.

**Method**

This is an experimental study, based on the comparison of HbA1c test results from two different populations: a test group represented by individuals heterozygous for hemoglobin variants (AS and AC) and a control group consisting of people with electrophoretic profile AA confirmed by hemoglobin electrophoresis at alkaline pH. Both populations were required to meet the inclusion criteria: Normal levels of fasting glucose, hemoglobin, urea and triglycerides, bilirubin > 20 mg/dL, and non-use of acetylsalicylic acid (ASA). All of the above factors, if changed, can trigger falsely high or low results.

In addition to the HbA1c test, other tests were performed in the two populations to contribute to the interpretation of HbA1c, such as: fasting blood glucose and blood counts, as well as tests to identify possible interferers: urea and triglycerides. Still assessing interferences, we checked if the samples were icteric, as bilirubin levels above 20 mg/dL can cause falsely high HbA1c results. We paid special attention to ascorbic acid, which influences the assessment of HbA1c.

The study divided groups by age group according to Ministry of Health criteria: children and adolescents aged 0-19 years, adults aged 20 to 60 years, and those older than 60 years.

We evaluated 50 individuals heterozygous for hemoglobin variants and 50 controls from August 2013 to May 2014.
Data were tabulated using statistical software, Microsoft Excel® and GraphPad Software, Inc., version Prism 6. Comparison of HbA1c levels between individuals heterozygous for hemoglobin variants and controls with no change in hemoglobin structure was performed based on standard deviation, mean and G-Test.

**RESULTS**

We analyzed 50 patients heterozygous for hemoglobin variants with normal blood glucose levels, of which 23 were male, representing 46% of the study population, and 27 were female, totaling 54%. Of the total 50, 16% are AC and the remaining 84% are AS.

Dividing the group by age, we found 39 adults with a mean age of 34.6 years (21 ± 38 years) and 11 children and adolescents with a mean age of 5.9 years, ranging from 1 to 13 years. In this group, no interferer was observed, as described in Table 1.

<table>
<thead>
<tr>
<th>Tests</th>
<th>Mean value</th>
<th>Minimum value</th>
<th>Maximum value</th>
<th>Reference value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Urea</td>
<td>27 mg/dL</td>
<td>17 mg/dL</td>
<td>39 mg/dL</td>
<td>15-40 mg/dL</td>
</tr>
<tr>
<td>Triglycerides</td>
<td>113 mg/dL</td>
<td>80 mg/dL</td>
<td>143 mg/dL</td>
<td>&lt; 150 mg/dL</td>
</tr>
<tr>
<td>Total bilirubin</td>
<td>0.9 mg/dL</td>
<td>0.6 mg/dL</td>
<td>1.2 mg/dL</td>
<td>≤ 1.2 mg/dL</td>
</tr>
<tr>
<td>Source: Clinical Laboratory at PUC Goiás</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

The mean values of HbA1c in heterozygous children were at 5.11%, with a minimum of 3.9% and maximum of 5.97%. The mean fasting glucose in this group was 89.56 mg/dL, ranging from a minimum of 75 mg/dL to a maximum of 97 mg/dL, while mean hemoglobin was 12.9 g/dL, ranging from 12.1 g/dL and 14 g/dL.

The mean A1c of heterozygous adults was close to the values found for children, at 5.0%, ranging from a minimum of 3.1% to a maximum of 6.9%. As for mean fasting blood glucose, the adult population presented 84 mg/dL, ranging from a minimum of 69 mg/dL to a maximum of 97 mg/dL. Mean hemoglobin was at 13.8 g/dL, ranging from 12.3 g/dL to 15.8 g/dL.

In order to compare the data, we analyzed the same tests in 50 patients without heterozygosity for hemoglobinopathies, with normal glycemic levels, of which 71.4% were female. This group included 11 children and adolescents, with a mean age of 10 years (6 ± 14 years). The following results were found in this class: HbA1c 5.78%, fasting blood glucose 78.8 mg/dL and hemoglobin 14 g/dL.

With regard to the adult control population, 39 people with mean age of 45 years (22 ± 37 years) were analyzed. We found in this group the following mean test results: HbA1c 5.84%, ranging from 4.1% to a maximum of 6.9%, fasting blood glucose at 89.3 mg/dL, ranging from 60 mg/dL to 99 mg/dL, and mean hemoglobin at 13.6 g/dL, ranging from a minimum of 12 g/dL to a maximum of 15.7 g/dL.

HbA1c standard deviation of the children was then calculated, reaching the result of 0.40 in the control group and 0.75 in the test group. The standard deviation from the adult test population was also calculated, which was 1.09 and the control was 0.57.

The value of the G-test was also determined, representing the result of HbA1c in the normal group compared to the altered group, reaching p=0.93 for children and p=0.89 for adults (Figures 1 and 2).

Of the 50 heterozygous individuals, ten had results below the lower limit of 4%. Of these, eight were adults and two were children, of whom nine were female. The electrophoretic pattern of this group was verified and eight fit the AS profile, while two were AC.

**DISCUSSION**

This study showed significant similarity with the findings of Menezes et al., whose comparative inferential analysis of HbA1c was: AA, AS, AC and SS obtained from blood samples from 150 participants, including diabetics, was not significant, the same being observed in our study with 100 subjects who had normal glycemic levels.

Yedla, Kuchay and Mithal evaluated the levels of fasting blood glucose, postprandial blood glucose, fructosamine and HbA1c (immunoassay technique) of a diabetic patient, resulting in higher levels of fasting blood glucose, postprandial blood glucose and fructosamine, but not HbA1c, which remained normal. They concluded that the result was underestimated, and a different technique should be performed for this type of examination.

According to the study, ion exchange chromatography (HPLC) as a method used to measure HbA1c is not influenced by heterozygous hemoglobinopathies, as Copeland et al. report that some methodologies may have interference from heterozygous hemoglobins.

In a study by Camargo and Gross, the authors analyzed more than 25,000 samples and found patients heterozygous for HbS, HbC or HbD, noting that the presence of a hemoglobin variant may yield lower (false) results. However, anemia is also a source of negative interference. The hematological status should be considered for the correct interpretation of GHB results.

Despite cation exchange, HPLC is the reference method, and the presence of hemoglobin variants may interfere with levels of HbA1c, yielding false high or low levels.
when the hemoglobin variant or its glycosylated form cannot be separated from hemoglobin A or HbA1c.23,24 In contrast, heterozygous hemoglobin S and C samples did not affect the assay.25

Not only hemoglobinopathies, including thalassemia syndromes, but also factors that affect red blood cell survival, age, uremia, hyperbilirubinemia and iron deficiency can affect the results of HbA1c tests. Racial and ethnic differences, genetic variation in hemoglobin glycation and assay methodology may also influence the results.26

New methods are being developed, such as mass spectrometry, which is based on the suppression of fluorescence of a boron eosin in acid solution, and shows minimal interference of the hemoglobin variants.27-30 Despite these valuable attributes, cost of equipment and complexity of the operation limit its use.31

According to studies, the presence of genetic variants of hemoglobin under heterozygous conditions may interfere with the measurement of HbA1c, resulting in falsely high or decreased values, depending on the type of test used.
Dosage of HbA1c does not apply in homozygous conditions to anomalous hemoglobins under any method, because, in these cases, hemoglobin A is practically absent. However, when an interfering hemoglobin variant is visualized or suspected, samples should be analyzed using an alternative method. In such cases, tests such as fructosamine and/or glycated albumin may be useful.\textsuperscript{2,21,31} Bouzid et al.\textsuperscript{32} suggest that laboratory professionals add a footnote that reads: "Quantification of HbA1c was not possible using this method due to the presence of homozygous HbS or HbC variants or heterozygous SC compounds. We suggest fructosamine or another alternative." This would provide the physician with the information needed to properly manage these diabetic patients.

Lower levels of hemoglobin affect A1c measurement and, since women have lower hemoglobin levels than men, the A1c result will suffer interference and the reference value should be different.\textsuperscript{33}

**CONCLUSION**

Our study evaluated HbA1c using ion exchange chromatography, and the patients heterozygous for hemoglobin variants did not present a significant difference compared to the control group.

Based on the results of this study, members of the medical community should consider an assessment of laboratory results due to the differences in method employed for diagnostic support. When assessing laboratory results, the interpretation must include patient history, which may contain data related to the ethnic and socioeconomic characteristics of that specific population.

**RESUMO**

Dosagem de hemoglobina glicada em heterozigotos para hemoglobinas variantes

**Objetivo:** Avaliar os níveis de hemoglobina glicada em pacientes heterozigotos para hemoglobinas variantes e comparar os resultados deste exame com grupo controle.

**Método:** Tratase de um estudo experimental, baseado na comparação do exame de hemoglobina glicada de duas populações diferentes, sendo um grupo teste, representado por indivíduos heterozigóticos para hemoglobinas variantes (AS e AC) e um grupo controle, constituído por pessoas com perfil eletroforético AA. As duas populações verificadas devem obedecer ao critério de inclusão: glicemia de jejum, hemoglobina, ureia e triglicerídeos normais, bilirrubina > 20 mg/dL e não fazer uso de ácido acetilsalicílico. Foram avaliados 50 indivíduos heterozigotos e 50 controles no período de agosto de 2013 a maio de 2014. A comparação dos valores de hemoglobina glicada entre indivíduos heterozigóticos e controle foi realizada por meio do desvio padrão, média e teste G.

**Resultados:** O estudo analisou um grupo teste e um grupo controle, ambos com 39 adultos e 11 crianças. A média dos adultos heterozigotos para HbA1c foi de 5,0%, o grupo controle apresentou índice de 5,7%. Já as crianças heterozigóticas obtiveram média de HbA1c de 5,11%, enquanto as normais apresentaram valores médios de 5,78%. O valor do teste G foi de p=0,9 para crianças e p=0,89 para adultos.

**Conclusão:** Este estudo avaliou HbA1c pela metodologia de cromatografia de coluna com resinas de troca iônica, em que pacientes com heterozigoses para hemoglobinas variantes não apresentaram uma diferença significativa em relação ao grupo controle.

**Palavras-chave:** hemoglobina A glicosilada, cromatografia por troca iônica, hemoglobinas.

**REFERENCES**


